ImpriMed, Inc.
PrivateLast Round
Series A
Extension
Sep 18, 2026
Est. Valuation
$47.52M
Total Funding Raised
$37.03M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
ImpriMed, Inc. is a precision medicine company that utilizes artificial intelligence and lab testing of live cancer cells to predict patient response to various cancer treatments.
Sector
Healthcare & Life Sciences
Verticals
Precision Medicine, Medical AI, Biotechnology, Healthcare Analytics
Business Model
B2B
Customer Profile
Usage-Based SaaS
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ImpriMed, Inc. Comparables
Compare ImpriMed, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| FidoCure | 85% | |
| VetOmics | 72% | |
| Anivive Lifesciences | 69% |
ImpriMed, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Sep 18, 2026 | ||||
| Series A | Dec 19, 2023 | ||||
| VC Round | Apr 13, 2021 | ||||
| Seed | Apr 12, 2019 | ||||
| Pre Seed | Jun 1, 2018 |
Key People
Founding team and executive leadership
ImpriMed, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Draper Dragon | VC Round |
| StartX | Seed |
| NAVER D2SF | Series A Extension |
| Plug and Play Tech Center | Seed, Pre Seed |
| Han River Partners | Series A |
| Murex Partners | VC Round, Series A, Seed |
| Samsung Securities Co., Ltd. | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 18, 2026
$10M round led by LB Investment.
- Mar 4, 2026
Helped over 11,000 dogs and cats with cancer.
Recent news
Latest coverage and updates
- receives_financingSep 23, 2026
ImpriMed, Inc. received financing of $10M in Series A2 on Sep 18th '26.
- is_developingSep 18, 2026
ImpriMed, Inc. is developing AI models trained on more than 3.5 million data points on Sep 18th '26.
- expands_offices_toSep 18, 2026
ImpriMed, Inc. expanded offices to Asia on Sep 18th '26.
- receives_financingSep 18, 2026
ImpriMed, Inc. received financing of $10M in Series A2 Bridge on Sep 18th '26.
ImpriMed, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about ImpriMed, Inc.'s valuation, stock price, and market status.
Is ImpriMed, Inc. a public or private company?
ImpriMed, Inc. is a private company.
What is the current stock price of ImpriMed, Inc.?
ImpriMed, Inc. is a private company with no public stock price. No recent secondary market data is available.
How much is ImpriMed, Inc. worth (valuation)?
Valuation information for ImpriMed, Inc. is not publicly available.
Can I buy ImpriMed, Inc. stock?
ImpriMed, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was ImpriMed, Inc.'s last funding round?
ImpriMed, Inc.'s most recent funding round was Series A on December 19, 2023.
Who are the main investors in ImpriMed, Inc.?
Key investors in ImpriMed, Inc. include SBVA, Draper Associates, HG Initiative, The Edgeof.
Will ImpriMed, Inc. IPO soon?
No public IPO plans have been announced for ImpriMed, Inc..
How can I track ImpriMed, Inc. secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ImpriMed, Inc.'s secondary market activity and sign up for updates.